Zeiler Gerhard

Zeiler (President, International) sold 600.0K WBD shares at $28.02 for $16.8M; retains 672.6K; -47.1% portfolio reduction

Zeiler executed a substantial open-market sale of 600,000 shares on 2026-03-04, reducing his WBD holdings by 47.1% and realizing $16,812,000.00 in proceeds at $28.02 per share. This is a material reduction in executive-level exposure to the company. His prior trades at WBD show mixed outcomes—one prior buy returned +10.0% over 90 days, while the other two prior buys declined 15.4% and 16.5% respectively, indicating only 1 of 3 prior buys at this ticker achieved positive 90-day returns. WBD is trading near its 52-week high of $29.98 (currently $28.00, -6.6% from peak), and the company is reporting net losses of $-148,000,000.00 on quarterly revenue of $9,045,000,000.00 with annual revenue declining 5.2%. The combination of near-peak pricing, significant portfolio reduction by a president-level officer, and underlying negative net income warrants investor attention to the motivations and broader strategic positioning within the company.

President Zeiler bought 58,000 WBD shares at $9.24; prior buys at this ticker both underwater after 90 days.

Zeiler Gerhard, President International, purchased 58,000 shares at $9.24 on 2024-11-11, expanding his holdings by 6.4% to 966,130 shares. The purchase occurs near the lower end of the 52-week range ($6.71–$12.49), and the stock has rebounded 32.5% over 90 days and 22.6% over 30 days from prior lows. However, his prior buy at this ticker on 2024-05-13 declined 15.4% over 90 days, and his earlier buy on 2023-08-07 fell 16.5% over 90 days—neither prior purchase at WBD proved well-timed. His cross-ticker track record shows 2 prior buys with an average 90-day return of -15.9% and a 0.00% win rate, indicating a consistent pattern of purchasing before further declines. The company reported quarterly revenue of $9.6B with annual growth of 22.2%, but remains unprofitable on a full-year basis, which may reflect operational or restructuring headwinds that weigh on stock recovery after insider purchases.